Preoperative Immunotherapy Increases Complete Response in Triple-Negative Breast Cancer

As is known, immunotherapies have demonstrated their effectiveness in many types of cancer and have entered clinical use. One of these areas is metastatic (stage 4) triple-negative breast cancer. Among these immunotherapies, atezolizumab (Tecentriq) has entered use after approval by the American Food and Drug Administration (FDA). We also know from studies that its use as preoperative neoadjuvant treatment is effective. Two studies in this area were presented at the San Antonio Breast Cancer Symposium. The breast cancer subtype that contains neither hormone receptors nor the HER2 receptor is called triple-negative breast cancer. It accounts for approximately 15% of all patients with breast cancer. In this subgroup, we generally prefer to administer chemotherapy before surgery and thus determine the rate at which patients benefit from treatment. The assessment that best demonstrates this benefit is the pathological examination of the tissue removed during surgery. We know from previous studies that breast cancer patients who achieve a pathological complete response have a 69% lower likelihood of disease recurrence . With the use of immunotherapies in triple-negative breast cancer, the question "Could immunotherapies increase the rate of pathological complete response in breast cancer?" has come to the fore. In this area, two different studies were presented at the San Antonio Breast Cancer Congress.
Pembrolizumab – KEYNOTE 522 Study
The study enrolled 600 patients with triple-negative breast cancer. Before surgery, one group received standard chemotherapy, while the other group received pembrolizumab (Keytruda) in addition to this standard chemotherapy. The chemotherapy regimen used carboplatin and paclitaxel for the first 4 cycles, followed by a combination of cyclophosphamide and adriamycin / epirubicin for the next 4 cycles. Patients with positive lymph node metastases accounted for 50% of the patients, while 83% had a positive PD-L1 score. The results showed that adding immunotherapy increased the pathological complete response rate by 13.6% in the overall group (64.8% versus 51.2%) and that event-free survival (EFS) was 6% better among those receiving immunotherapy (91% versus 85). When the subgroups were evaluated, the rate of complete benefit was much higher in those whose PD-L1 score positivity was above 20% (82% versus 62). In particular, among patients whose disease had spread to the armpit, immunotherapy was shown to increase complete response by an additional 20% (64.8% versus 44.1%). Side effects in terms of side effects: approximately 78% of patients in both groups were able to receive all of their chemotherapy. Hypothyroidism and skin changes were more common among patients receiving immunotherapy. However, all the side effects were manageable. - Related topic: What are the side effects of immunotherapy drugs, and how are they treated?
Atezolizumab – NeoTRIPaPDL1 Study
The study enrolled 280 patients with high-risk early-stage disease and locally advanced disease. Unlike the other study, surgery was performed after 4 cycles of carboplatin-paclitaxel chemotherapy. The remaining 4 cycles of cyclophosphamide and adriamycin chemotherapy were administered after surgery. Of the patients enrolled in this study, 56% were PD-L1 positive. The proportion of patients whose disease had not spread to the armpit (lymph node negative) was 13%. Adding atezolizumab contributed an additional 2.7% in terms of pathological complete response (43.5 versus 40.8). In both patient groups, the complete response rate was higher among patients who were PD-L1 positive. In other words, the presence of PD-L1 was shown to be the most important factor determining treatment response. The clinical benefit rate was 8% higher with immunotherapy (76% versus 68%). Serious (grade 3-4) side effects were 10% more frequent among those receiving atezolizumab. The drug discontinuation rates were the same in both groups. The results for 5-year event-free survival (EFS) in this study are awaited. Detailed analyses including BRCA1 and 2 genetic carrier status, which we encounter in triple-negative breast cancer, are also awaited.
Conclusion
Considering both studies, pathological complete response is very important in patients receiving neoadjuvant treatment. Some previous studies of different immunotherapies found that immunotherapy increased the likelihood of achieving a pathological complete benefit in breast cancer, whereas others found no effect. We believe that the difference between these two studies is related to this patient selection. In addition, in my opinion, the different timing of surgery in the atezolizumab study is an important factor reducing the complete response rate. We believe that preoperative immunotherapy will increase treatment effectiveness, particularly in patients with locally advanced triple-negative breast cancer. Pembrolizumab, in particular, appears likely to take its place in the new treatment strategy for patients with triple-negative breast cancer on the basis of this study. We need to see the results of detailed subgroup analyses of both studies, as well as additional genetic analyses such as BRCA mutation analyses.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.